An2 Therapeutics Inc (ANTX)

$ANTX slow climber…..

$ANTX loading here

$ANTX This collaboration marks a transformative acceleration in AN2’s pipeline—with a realistic shot at delivering a trusted, first-ever oral Chagas treatment. A major long-term value builder.

$ANTX AN2 Therapeutics teams up with DNDi (Drugs for Neglected Diseases initiative) to co-develop a novel oral compound aimed at treating chronic Chagas disease—marking a major step forward in global health.

$ANTX watching today

$ANTX keep on watch for a breakout 👀

🚨 $ANTX has just announced a new partnership today with DNDi to develop an oral treatment for chronic Chagas disease. This follows a 200-patient Melioidosis study update last month and signs of insider buying near the bottom. Institutions like RA Capital and TCG still hold, and JMP has maintained a $5 target throughout 2025. The float is 17M, insider ownership is 43%, and the chart is pressing a breakout level with MACD flipped and no dilution in play. If this reclaims 1.16 with volume, it can move toward 1.25–1.30 fast https://www.businesswire.com/news/home/20250723721725/en/AN2-Therapeutics-and-DNDi-Collaborate-on-Clinical-Development-of-Promising-New-Oral-Compound-to-Treat-Chronic-Chagas-Disease Key Levels: Targets: 1.19 / 1.25 / 1.31+ Stop: 1.07

$ANTX @MS_Tammy @Santa_Claus_Trades

$ANTX load up

$ANTX https://www.businesswire.com/news/home/20250723721725/en/AN2-Therapeutics-and-DNDi-Collaborate-on-Clinical-Development-of-Promising-New-Oral-Compound-to-Treat-Chronic-Chagas-Disease

$ANTX pt $2+

$ANTX Precision BioSciences just received FDA Orphan Drug Designation for PBGENE‑DMD, its in vivo ARCUS® gene-editing therapy for Duchenne Muscular Dystrophy (DMD)

$ANTX news👀

$ANTX Loading --------

$PSTV 🔥🔥 $WBUY $GVH $ANTX $IPDN

$ANTX 07:11 on Jun. 30 2025 AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime #tradeideas

$ANTX AN2 Therapeutics completes 200-patient observational study in acute melioidosis AN2 Therapeutics announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial infection and recognized biothreat. The study, conducted under real-world conditions in acute hospital settings, evaluated patients receiving the current standard of care: IV meropenem or ceftazidime. Completed under a contract funded entirely by the National Institutes of Health, the study was completed in just 11 months across three sites in acute melioidosis-endemic regions, demonstrating efficient enrollment and strong site engagement. The study generated an important follow-up dataset for patients treated for acute melioidosis with current standard of care antibiotics, tracking patients for over 90 days. The results revealed a striking mortality rate of nearly 40% among confirmed melioidosis cases. Principal Investigators observed that approximately 25% of screened patients died in the short period before a definitive diagnosis of infection with the causative pathogen was confirmed and were not included in the topline mortality rate. These mortality findings highlight the serious impact of melioidosis, the critical importance of early detection and the urgent need for more effective treatment options. Due to its high mortality and ease of environmental acquisition, B. pseudomallei is classified as a high priority biothreat agent. If approved for the treatment of acute melioidosis, the Company would seek a priority review voucher and could generate revenue from U.S. and other government stockpiling, as well as from use as a treatment in disease endemic countries, including the U.S.

$ANTX another good day on overnight swings for us with all winners.... Now we took this one for tomorrow small float big volume.. $1.21 major resistance breaks this should head for $1.55 next leg up 🚨 🚨

$ANTX is looking good here for a swing with major catalysts ahead. Strong cash position for 3+ years runway and multiple data readouts. Potential for non dilutive funding as well. This is primed to bounce $CERO $ACXP $RBNE

$ANTX see this one going to $3 EOW

$ANTX couple members of management held roles in Anacor Pharmaceuticals, which was bought out by Pfizer for $5.2B. Management has had successful prior experience with boron based drugs $NCNA $HCTI $KLTO

$ANTX liking this stock here. Couple catalysts coming with data readouts set for next couple months Non dilutive funding news is imminent, could be some major partnership with big pharma, with an upfront payment + milestone structure🚀 $NCNA $HCTI $KLTO